C1q |
MM anti-C1q mAb (WL02, Hycult) |
MM anti-C1q (DJ01, Hycult)-HRP |
C1q (in-house purified) |
32–1000 |
1:1000 |
C3 |
RP anti human C3 (in-house) |
RP anti-C3 (in-house)-HRP |
C3 (CompTech) |
32–1000 |
1:16,000 |
C4 |
RP anti-C4 (in-house) |
RP anti-C4 (in-house)-HRP |
C4 (CompTech) |
8–500 |
1:4000 |
C5 |
RP anti-C5 (in-house) |
MM anti-C5 (2D5; in-house)-HRP |
C5 (in-house purified) |
32–1000 |
1:200 |
Factor B |
MM anti-FB (JC1; in house) |
MM anti-FB (MBI-5; in-house)-HRP |
FB (in-house purified) |
64–1000 |
1:500 |
Factor H |
MM anti-FH (OX24; ECACC) |
MM anti-FH (35H9; in-house)-HRP |
FH (in-house purified) |
16–1000 |
1:3000 |
C1inh |
MM anti-C1inh (in-house) |
RP anti-C1inh (in-house)-HRP |
C1 inhibitor (Cinryze drug) |
4–100 |
1:16,000 |
Properdin |
MM anti-properdin (1.1.1; Gift of SRdC) |
MM anti-properdin (12-14-2; gift of SRdC)-HRP |
Properdin (CompTech) |
7–100 |
1:400 |
FHR125 |
MM anti-FHR125 (MBI125; in-house) |
RP anti-FH (in-house)-HRP |
FHR125 (in-house) |
4–250 |
1:4000 |
TCC |
MM anti-TCC (aE11, Hycult) |
MM anti C8 (E2, in-house)-HRP |
TCC (in-house purified) |
60–1000 |
1:50 |
CR1 |
RP anti-CR1 (in-house) |
MM anti-CR1 (MBI35; in-house)-HRP |
CR1 (in-house purified) |
16–500 |
1:2 |
CRP |
MM anti-CRP (R&D systems; DuoSet) |
MM anti-CRP-biotin/avidin-HRP (R&D systems; DuoSet) |
CRP (R&D systems; DuoSet) |
0.8–50 |
1:200 |